Successful management of a high-risk acute myeloid leukemia patient with severe coronary heart disease by venetoclax plus azacytidine and coronary artery bypass grafting
J Transl Int Med. 2024 Mar 21;12(1):119-122.
doi: 10.2478/jtim-2023-0139.
eCollection 2024 Feb.
1 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
2 Cardiology Department, Peking University People's Hospital, Beijing, China.
3 Cardiac Surgery Department, Peking University People's Hospital, Beijing 100044, China.
4 Department of Transfusion, Peking University People's Hospital, Beijing 100044, China.
5 Peking-Tsinghua Center for Life Sciences, Beijing 100871, China.
6 Collaborative Innovation Center of Hematology China, Peking University, Beijing 100871, China.
The work was supported by the National Key Research and Development Program of China (2021YFC2500300), Peking University People’s Hospital Research and Development Funds (RDL2022–13).